Ge Healthcare Technologies (GEHC) Stock
Global medical technology company for imaging and patient monitoring. Here's the price, business snapshot, and what's worth knowing about Ge Healthcare Technologies in June 2026.
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and services company focused on diagnostic imaging, ultrasound, patient monitoring, life‑sciences tools and bioprocessing, and healthcare IT. With a market capitalisation around $34.7 billion, the business combines capital equipment sales with recurring revenue from service contracts, consumables and software – a mix that can smooth cyclicality in equipment purchases. Key growth drivers include demand for imaging and diagnostics, expansion of bioprocessing for biologics, and adoption of digital and AI tools to improve workflows. Investors should be aware of sensitivity to hospital and clinic capital spending cycles, competitive pressures, reimbursement and regulatory risk, and supply‑chain dynamics. Management execution and capital allocation also matter for returns. This summary is educational only, not personalised advice: values can rise and fall and past performance is not a guide to the future. Check up‑to‑date filings and consult a financial adviser when assessing suitability for your portfolio.
Why It’s Moving
GE HealthCare Shares Surge as 2026 Profit Outlook Beats Expectations on Unstoppable Medical Device Demand
- Fiscal 2026 profit projections surpassed market expectations, signaling that strong demand for medical devices is translating into tangible revenue growth rather than just volume increases.
- Operational improvements and the rollout of AI-enhanced diagnostic tools are cited as primary catalysts, indicating that technology integration is successfully driving market differentiation.
- Analyst consensus has shifted to a 'Buy' rating with a target implying over 16% upside, reflecting confidence that the company's strategic pivot toward high-value healthcare solutions will sustain long-term momentum.
GE HealthCare Shares Surge as 2026 Profit Outlook Beats Expectations on Unstoppable Medical Device Demand
- Fiscal 2026 profit projections surpassed market expectations, signaling that strong demand for medical devices is translating into tangible revenue growth rather than just volume increases.
- Operational improvements and the rollout of AI-enhanced diagnostic tools are cited as primary catalysts, indicating that technology integration is successfully driving market differentiation.
- Analyst consensus has shifted to a 'Buy' rating with a target implying over 16% upside, reflecting confidence that the company's strategic pivot toward high-value healthcare solutions will sustain long-term momentum.
When is the next earnings date for GE HEALTHCARE TECHNOLOGIES INC (GEHC)?
The next earnings date for GEHC is currently estimated for July 29, 2026. It is expected to cover Q2 2026 results. GE HealthCare has not formally confirmed the date yet, but this timing matches its typical late-July reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding GE Healthcare's stock with a target price of $89.6, indicating potential growth.
Financial Health
GE Healthcare is performing well with strong earnings, cash flow, and revenue figures.
Dividend
GE Healthcare's dividend yield of 0.22% is low, which may not attract income-focused investors. If you invested $1000, you would be paid $2.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring GEHC
Singapore Applied AI Hub Stocks to Watch in 2026
OpenAI has signed its first government MOU to establish an applied AI lab in Singapore, committing over S$300 million to build the city-state into a global hub for real-world AI deployment. This partnership opens the door for companies across enterprise AI software, cloud infrastructure, healthcare AI, and workforce development to expand their footprint across Southeast Asia.
Published: 20 May 2026
Explore BasketRadiopharma Revolution: Promise Meets Market Risk
Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.
Published: 9 January 2026
Explore BasketDow Record Rally: What's Next for Value Stocks?
The Dow Jones Industrial Average reached a historic high, closing above 48,000, fueled by the end of a government shutdown and a market rotation into value stocks. This shift suggests an investment opportunity in the outperforming healthcare and financial sectors, which are leading the charge.
Published: 13 November 2025
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketARK Innovation ETF: What's Next for Africa's Growth?
Africa's digital economy is rapidly expanding, creating demand for cutting-edge technologies in finance, healthcare, and energy. This basket offers potential exposure to US-listed companies leading the disruptive innovation trends that are shaping the continent's future.
Published: 15 September 2025
Explore BasketHealthcare's Efficiency Imperative
UnitedHealth Group's recent profit miss, driven by high medical costs, has triggered a major cost-cutting initiative across the company. This move signals a broader industry trend, creating an investment opportunity in companies that provide AI and technology solutions to help healthcare organizations improve efficiency and reduce operational expenses.
Published: 30 July 2025
Explore BasketHealthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: 26 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics and Imaging
Imaging equipment drives sales and higher‑margin service revenue; technological upgrades and AI could support demand, though hospital budgets and reimbursement affect timing.
Life Sciences Growth
Bioprocessing and tools for biologics offer expansion opportunities as biologics production rises, but competition and capital intensity can affect margins.
Global Service Network
Recurring revenue from service contracts and consumables provides stability and customer ties, yet geographic exposure and supply chains can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
